Explanatory review on DDR inhibitors: their biological activity, synthetic route, and structure–activity relationship
Molecular Diversity · 2025-12 · 29 (6) · 5153-5183
DOI: 10.1007/s11030-024-11091-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Diversity, online erschienen am 30.01.2025. Verfasst von Sindhuja Sengupta und 7 weiteren Autor:innen. Beteiligte Einrichtung: Integrated Drug Discovery Centre, Department of Pharmaceutical Chemistry, Acharya & BM Reddy College of Pharmacy, Bengaluru, 560107, Karnataka, India. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Discoidin Domain Receptors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 100 Literaturangaben.
Abstract (Originalsprache)
Discoidin domain receptors (DDR) are categorized under tyrosine kinase receptors (RTKs) and play a crucial role in various etiological conditions such as cancer, fibrosis, atherosclerosis, osteoarthritis, and inflammatory diseases. The structural domain rearrangement of DDR1 and DDR2 involved six domains of interest namely N-terminal DS, DS-like, intracellular juxtamembrane, transmembrane juxtamembrane, extracellular juxtamembrane intracellular kinase domain, and the tail portion contains small C-tail linkage. DDR has not been explored to a wide extent to be declared as a prime target for any particular pathological condition. Very few scientific data are available so there is a need to study the receptors and their inhibitors. Still, there did not exist FDA-approved small molecules targeting DDR1 and DDR2 receptors so there is an urgent need to develop potent small molecules. Further, the structural features and ligand specificities encourage the researchers to be fascinated about the DDR and explore them for the mentioned biological conditions. Therefore, in the last few years, researchers have been involved in investigating the potent DDR inhibitors. The current review provides an outlook on the anatomy and physiology of DDR, focusing on the structural features of DDR receptors and the mechanism of signaling pathways. We have also compiled the evolutionary development status of DDR inhibitors according to their chemical classes, biological activity, selectivity, and structure-activity relationship. From biological activity analysis, it was revealed that compounds 64a (selectivity: DDR1) and 103a (selectivity: DDR2) were the most potent candidates with excellent activity with IC50 values of 4.67 and 3.2 nM, respectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Integrated Drug Discovery Centre, Department of Pharmaceutical Chemistry, Acharya & BM Reddy College of Pharmacy, Bengaluru, 560107, Karnataka, India.
- NEF College of Pharmaceutical Education & Research, Nagaon, 782001, India.
- Tarifa Memorial Institute of Pharmacy, Murshidabad, West Bengal, 742166, India.
- School of Pharmacy, Sangam University, Atoon, Bhilwara, Rajasthan, 311001, India. ghanshyamsahu203@gmail.com.
- Integrated Drug Discovery Centre, Department of Pharmaceutical Chemistry, Acharya & BM Reddy College of Pharmacy, Bengaluru, 560107, Karnataka, India. gurubasavarajaswamy@gmail.com.
ORCID-Profile: Gurubasavaraja Swamy Purawarga Matada
Zitieren
APA
Sengupta, S., Maji, L., Das, P. K., Teli, G., Nag, M., Khan, N., Haque, M., & Matada, G. S. P. (2025). Explanatory review on DDR inhibitors: their biological activity, synthetic route, and structure–activity relationship. Molecular Diversity, 29(6), 5153-5183. https://doi.org/10.1007/s11030-024-11091-5
Vancouver
Sengupta S, Maji L, Das PK, Teli G, Nag M, Khan N, et al. Explanatory review on DDR inhibitors: their biological activity, synthetic route, and structure–activity relationship. Molecular Diversity. 2025;29(6):5153-5183. doi:10.1007/s11030-024-11091-5
BibTeX
@article{Sengupta2025,
author = {Sengupta, Sindhuja and Maji, Lalmohan and Das, Pronoy Kanti and Teli, Ghanshyam and Nag, Mrinmoy and Khan, Nirmalya and Haque, Mridul and Matada, Gurubasavaraja Swamy Purawarga},
title = {Explanatory review on DDR inhibitors: their biological activity, synthetic route, and structure–activity relationship},
journal = {Molecular Diversity},
year = {2025},
volume = {29},
number = {6},
pages = {5153--5183},
doi = {10.1007/s11030-024-11091-5}
}
EUVIMED